Lyell Immunopharma (NASDAQ:LYEL) Releases Earnings Results, Beats Expectations By $0.01 EPS

Lyell Immunopharma (NASDAQ:LYEL) announced its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01, Zacks reports. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The business had revenue of $0.01 million during the quarter.

Lyell Immunopharma Trading Down 3.6%

NASDAQ LYEL opened at $0.39 on Thursday. The company has a 50-day moving average price of $0.48 and a two-hundred day moving average price of $0.67. The stock has a market cap of $115.18 million, a price-to-earnings ratio of -0.49 and a beta of -0.25. Lyell Immunopharma has a 52 week low of $0.39 and a 52 week high of $2.88.

Insider Activity

In other news, CFO Charles W. Newton purchased 200,000 shares of Lyell Immunopharma stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $0.56 per share, for a total transaction of $112,000.00. Following the transaction, the chief financial officer now owns 200,000 shares in the company, valued at $112,000. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Richard Klausner purchased 158,000 shares of Lyell Immunopharma stock in a transaction that occurred on Friday, March 14th. The stock was purchased at an average price of $0.60 per share, with a total value of $94,800.00. Following the transaction, the director now owns 843,365 shares in the company, valued at $506,019. This represents a 23.05% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 768,640 shares of company stock worth $449,508 over the last three months. Corporate insiders own 25.10% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research report on Wednesday, April 16th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.